Core Points - The company has approved a cash dividend distribution plan for the fiscal year 2024, which will be distributed at a rate of 3.50 RMB per 10 shares (including tax) [1][2] - The total number of shares for the dividend distribution is based on the existing total share capital of 587,568,600 shares, excluding any repurchased shares [1][2] - The dividend distribution date is set for May 29, 2025, with the ex-dividend date on May 30, 2025 [2][3] Dividend Distribution Details - The cash dividend of 3.50 RMB per 10 shares will be distributed to all shareholders, with different tax treatments for various types of investors [1][2] - For Hong Kong market investors and certain foreign institutions, the net dividend after tax will be 3.15 RMB per 10 shares [1][2] - The company will not withhold individual income tax at the time of distribution; tax will be calculated based on the holding period when shares are sold [2] Shareholder Information - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of the close of trading on May 29, 2025 [2][3] - The distribution will be directly credited to the shareholders' accounts through their securities companies or other custodians [2][3] - The company assumes all legal responsibilities for any issues arising from insufficient cash dividends due to a decrease in shares held by shareholders during the distribution application period [2]

证券代码：002275 证券简称：桂林三金 公告编号：2025-021 桂林三金药业股份有限公司 2024年年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林三金药业股份有限公司（以下简称 "公司"）2024 年年度利润分配方 案已获 2025 年 5 月 16 日召开的 2024 年度股东大会审议通过，现将分红派息事 宜公告如下： 一、股东大会审议通过利润分配方案等情况 1.2024 年年度利润分配方案已获 2025 年 5 月 16 日召开的 2024 年度股东大 会审议通过，具体方案为：以未来实施分配方案时股权登记日的总股本为基数， 向全体股东每 10 股派发现金股利 3.50 元（含税），不送红股，不以资本公积转 增股本。根据公司现有总股本 587,568,600 股为基数，预计共分配现金股利 205,649,010.00 元(含税)；如公司在实施权益分派的股权登记日前公司总股本 及应分配股数发生变动的，拟维持每股分配比例不变的原则，相应调整利润分配 总额。 2.公司回购专用证券账户中的股份不参与本次权益分派，截至目前，公司回 ...

Group 1: Report Core Information - Reported company: Guilin Sanjin [16] - Industry: Traditional Chinese medicine [2] - Research date: May 20, 2025 [16] Group 2: Research Basic Information - Research object: Guilin Sanjin [16] - Industry: Traditional Chinese medicine [16] - Reception time: 2025 - 05 - 20 [16] - Reception staff: Host, Chairman and President Zou Xun, Director, Vice - President and Financial Officer Xie Yuan'gang, Vice - President and Board Secretary Li Chun, Independent Director Chen Liang [16] Group 3: Detailed Research Institutions - Reception object: All investors [19] - Reception object type: Others [19] - Reception method: Network remote [19] Group 4: Main Content Big Pharmacy - Reason for loss: Store expansion leading to large expenditures [23] - Function: An important part of the company's marketing strategy, expanding sales channels and perfecting the industrial chain [23] Sales Revenue Composition - Main income sources: Most from Chinese patent medicines, some from chemical drugs of Hunan Sanjin, and some from daily - chemical health products [23] - Key varieties: First - tier varieties like Sanjin Tablets series and Watermelon Frost series; second - tier varieties like Xuanyunning and Gejie Dingchuan Capsules; third - tier varieties in market development stage with small proportion [23] Dividend Policy - 2024 annual equity distribution plan: Proposed to distribute 3.5 yuan per 10 shares, totaling 206 million yuan in cash dividends, and also disclosed the 2025 mid - term cash dividend plan [24] Watermelon Frost Toothpaste - Product series: Yayanqing, Classic Anti - inflammation, Qingyan Toothpaste, etc. [25] - Current situation: Currently building sales channels, listed and promoted in second - tier and lower cities nationwide, mainly through supermarket channels and supplemented by online sales. The overall scale is small but in the growth stage [25] - Future plan: Leverage the company's advantages to expand the market scale [25] Subsidiaries in Shanghai - Baifan Bio: Affected by the investment and financing environment, with some idle production capacity in the short - term, but business development and customer resource accumulation have increased compared to 2023 [25] - Baichuan Bio: Multiple project pipelines are in the new drug R & D stage, with only a small amount of income from technical services, small revenue scale, large R & D expenditure [25] - Measures: Control costs and expenses, optimize the personnel structure, hire professional consulting companies, optimize R & D pipelines, and focus on projects like BC006 monoclonal antibody injection [26] New Drug R & D Progress - Progress: Advancing steadily according to the plan, and relevant information will be announced when significant progress is made [26] Second and Third - tier Varieties - Growth trend: Overall growth is better than first - tier varieties. Gejie Dingchuan Capsules may continue last year's growth rate; Xuanyunning series aims for double - digit growth this year; Lamotrigine Tablets aim to reach 100 million yuan in sales this year; other varieties strive for continuous breakthroughs and high growth rates [26][27]

Group 1 - The core revenue of the company primarily comes from traditional Chinese medicine, with contributions from chemical drugs and daily health products [1] - The company is focusing on expanding its sales channels for its watermelon frost toothpaste series, which includes various products and is currently being promoted in second-tier and lower cities [1] - The company plans to leverage its brand recognition and capital market advantages to strengthen its market position in daily health products [1] Group 2 - The overall development trend for the company's second and third-tier products is positive, with continued support for these products [2] - The company aims for double-digit growth in the sales of the dizziness relief series, which surpassed 100 million yuan in sales in 2021 [2] - The losses from the large pharmacy chain are attributed to significant expansion costs, and the chain is currently focused on the Guilin area to enhance the company's marketing strategy and sales channels [2]

Group 1: Company Overview - Guilin Sanjin Pharmaceutical Co., Ltd. is listed under stock code 002275 and is known for its focus on traditional Chinese medicine and health products [1]. Group 2: Financial Performance - The company plans to distribute a cash dividend of 3.5 CNY per 10 shares, totaling 206 million CNY for the 2024 fiscal year [3]. - The company has maintained a consistent cash dividend policy since its listing, ensuring stable cash flow for operations and development [3]. Group 3: Sales Composition - The majority of sales revenue comes from traditional Chinese medicine, with significant contributions from first-line products like Sanjin Pian and Xigua Frost series [3]. - Second-line products, such as Zhuan Yun Ning and He Qie Ding Chuan capsules, are expected to see growth, while third-line products are still in the market development phase [3]. Group 4: Business Strategy - The company is expanding its retail pharmacy operations, which faced losses due to high expansion costs, but is seen as a crucial part of the marketing strategy [2]. - The company is investing in the development of its personal care products, including Xigua Frost toothpaste, with a focus on expanding sales channels [3]. Group 5: R&D and Future Prospects - The company is actively pursuing new drug research and development, with ongoing projects expected to yield significant results [4]. - The second and third-line products are projected to have a positive growth trend, with specific targets set for various products to achieve substantial sales milestones [4].

Summary of the Shareholders' Meeting of Guilin Sanjin Pharmaceutical Co., Ltd. Core Viewpoint The shareholders' meeting of Guilin Sanjin Pharmaceutical Co., Ltd. was conducted in compliance with relevant laws and regulations, with all proposed resolutions being approved by the shareholders present. Group 1: Meeting Procedures - The shareholders' meeting was convened by the company's eighth board of directors and announced in advance, detailing the time, location, voting methods, and agenda [1][2][3] - The meeting utilized a combination of on-site voting and online voting, held on May 16, 2025, at the company's conference room in Guilin [2][3] - The legal compliance of the meeting's procedures was verified by the appointed lawyers, confirming adherence to the Company Law and the company's articles of association [4][5] Group 2: Attendance and Voting - A total of 82 shareholders and representatives attended the meeting, representing 417,031,460 shares, which is 70.9758% of the total voting shares [3][4] - Among the attendees, 15 were present at the venue, representing 412,512,257 shares (70.2067%), while 67 participated via online voting, representing 4,519,203 shares (0.7691%) [3] - The attendance included 76 minority shareholders, representing 14,315,780 shares (2.4364%) [3] Group 3: Voting Results - All proposed resolutions were passed with overwhelming support, including the annual report, board and supervisory committee reports, financial statements, and profit distribution plans [6][7][8][9][10] - For the first resolution regarding the 2024 annual report, 417,013,260 shares (99.9956%) voted in favor, with only 5,200 shares (0.0031%) against [6] - The resolutions concerning the remuneration of directors and senior management were also approved, with votes consistently exceeding 99% in favor [11][12][13][14][15] Group 4: Legal Opinion - The lawyers concluded that the meeting's convening, attendance, voting procedures, and results were all legally valid and in accordance with the relevant laws and regulations [23][24]

一、 本次股东大会的召集与召开程序 本次股东大会由公司第八届董事会第十三次会议决议召集。公司于 2025 年 4 月 26 日在《中国证券报》《证券时报》《证券日报》及巨潮资讯网 （www.cninfo.com.cn）上公告了《关于召开 2024 年度股东大会的通知》（以下 简称"会议通知"），会议通知载明了本次股东大会的召开时间和地点、投票方 式、会议召开方式、股权登记日、出席人员、会议审议事项和提案、会议登记相 关事项等内容。 本次股东大会采取现场表决和网络投票相结合的表决方式。本次股东大会现 场会议于 2025 年 5 月 16 日 14:30 在广西桂林市临桂区人民南路 9 号公司四楼会 议室如期举行。网络投票时间为：（1）通过深圳证券交易所交易系统进行网络 投票的具体时间为：2025 年 5 月 16 日 9:15-9:25，9:30-11:30 和 13:00-15:00；（2） 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间 为：2025 年 5 月 16 日 9:15-15:00 期间的任意时间。 关于桂林三金药业股份有限公司 2024 年 ...

Inventory Management - The company has upgraded its inventory management system, utilizing a BI intelligent analysis system and a professional data analysis team to balance market demand dynamics and cost control [1] - The overall inventory level has significantly decreased compared to the same period last year, maintaining a healthy inventory cycle of 1.5 to 2 months [1] Product Growth Potential - The growth trend for the company's second and third-line products is positive, with specific products like the Hejia Danchuan capsule expected to maintain last year's growth rate [1] - The Xuanyunning series has surpassed 100 million in sales in 2021, aiming for double-digit growth this year [1] - Other products, such as Shuyanquing spray and Fufang Ganmaoling granules, are also expected to maintain high growth rates [1] Dividend Policy - The company has consistently implemented a cash dividend policy, proposing a cash dividend of 3.5 yuan per 10 shares for 2024, totaling 206 million yuan [2] - The dividend policy is expected to remain stable unless there are special funding needs [2] Biopharmaceutical Development - Biopharmaceuticals are a key part of the company's dual strategy, facing high investment and risk, with the industry currently experiencing a downturn [2] - The company is optimizing its R&D pipeline, focusing on projects with promising clinical data, such as the BC006 monoclonal antibody injection, which is nearing the completion of Phase I clinical trials [2] - Efforts are being made to control costs and expenses while seeking partnerships in the biopharmaceutical sector [2]

证券代码：002275 证券简称：桂林三金 编号：2025-020 桂林三金药业股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示 1.本次股东大会未出现否决提案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1.召开时间： （1）现场会议召开时间：2025年5月16日14:30； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为2025年5 月16日9:15—9:25,9:30—11:30 和13:00—15:00；通过深圳证券交易所互联网 投票系统（http://wltp.cninfo.com.cn）投票时间为2025年5月16日9:15-15:00 期间的任意时间。 2.现场会议召开地点：广西壮族自治区桂林市临桂区人民南路9号公司四楼 会议室 3.召开方式：现场投票与网络投票相结合的方式 4.召集人：公司董事会 5.主持人：董事长邹洵先生 6.公司已于2025年4月26日在《中国证券报》《证券时报》《证券日报》及 巨潮资讯网发布了《关于召开2024年度股东大会的 ...

证券代码：002275 证券简称：桂林三金 公告编号：2025-019 桂林三金药业股份有限公司 关于召开2024年度业绩说明会并征集问题的公告 2.召开方式：网络远程文字交流的方式。 3. 参 与 方 式 ： 投 资 者 可 登 录 深 圳 证 券 交 易 所 " 互 动 易 " 平 台 （http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次年度业绩说明会。 4.公司出席人员：董事长、总裁邹洵先生，董事、副总裁兼财务负责人谢元 钢先生，副总裁兼董事会秘书李春先生，独立董事陈亮先生。 二、投资者问题征集事宜 为充分尊重投资者、提升交流的针对性，现就公司2024年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可在本次业绩说 明会召开前登录深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn） 进入"业绩说明会提问预征集"专题页面或扫描下方二维码提交问题，公司将在 2024年度业绩说明会上对投资者普遍关注的问题进行回答。业绩说明会召开交流 期间，投资者仍可登录活动界面进行互动提问。 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 ...